Compare Intuit Inc. (INTU) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Viatris Inc — how do they compare? Intuit Inc. trades at $356.02 (market cap $91.56B), while Viatris Inc trades at $16.06 (market cap $18.49B). The key difference: Intuit Inc. is far larger — about 5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.98%). Which is the better fit depends on your goals.
| INTU | VTRS | |
|---|---|---|
Market Cap | $91.56B | $18.49B |
Sector | Technology | Health |
52-Week High | $717.21 | $17.86 |
52-Week Low | $255.07 | $9.49 |
Enterprise Value | $90.01B | $30.61B |
Dividend Yield | 1.43% | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $358.29, up 6.49% in the last session, with a bullish technical outlook supported by moving averages and strong support at $331. The company shows robust fundamentals, with revenue growing to $18.83B in 2025 and net income margin expanding to 20.54%, while consistently beating EPS estimates. Recent news highlights legal investigations into potential securities fraud following a 20% stock drop, creating mixed sentiment.
The outlook remains positive due to solid earnings growth and a consensus price target of $402.26, but risks include ongoing legal scrutiny and competitive pressures in financial software. Investors should weigh strong profitability against regulatory and sentiment headwinds.
Viatris (VTRS) trades at $16.04, down 1.47% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.69 exceeding expectations by 14.8%. Recent FDA approval for Gwyn Lo contraceptive patch and divestiture of Tyrvaya nasal spray demonstrate strategic portfolio optimization. Revenue trends show stabilization after declining from $16.3B in 2022 to $14.3B in 2025, with 2026 projections at $14.7B.
While Viatris shows operational strength with consistent cash flow generation and debt reduction, the company faces profitability challenges with negative net income margins and elevated P/E ratio of 236.2. Analyst sentiment is cautiously optimistic with 30.8% buy ratings, though the majority (61.5%) recommend hold. Key risks include ongoing margin pressure, generic drug pricing headwinds, and execution of strategic initiatives amid competitive pharmaceutical landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
